Literature DB >> 32131750

Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients.

Yutuan Wu1,2, Shuang Ye1,2, Shyamal Goswami3, Xuan Pei1,2, Libing Xiang1,2, Xiaoming Zhang3, Huijuan Yang4,5.   

Abstract

BACKGROUND: Alterations in peripheral blood lymphocytes in cervical cancer have been reported, although conflicting views exist. The present study investigated the distributions of lymphocyte subsets in tumor tissue and peripheral blood samples from cervical cancer patients and precancerous lesion patients, and evaluated the correlations of lymphocyte subsets with clinicopathological and prognostic variables.
METHODS: A total of 44 patients with stage IB1-IIA2 cervical cancer and 13 precancerous lesion patients were included. Lymphocytes were collected from the tumor tissue and the peripheral blood, and isolated by Lymphoprep density gradient centrifugation. The percentages of lymphocyte subsets were quantified by flow cytometry analysis, and the differences between lymphocyte subsets in the tumor tissue and peripheral blood were compared by SPSS. In addition, the relationships between lymphocyte subsets and clinicopathological and prognostic variables were analyzed.
RESULTS: Our results revealed that the amount of total T lymphocytes, CD8+ T cells, granulocytes, pDCs, CD16+ monocytes and CD56high NK cells were significantly higher in the tumor tissue than in the peripheral blood in the cervical cancer patients, while those of CD4+ T cells, CD4+/CD8+ cell ratio, rdT cells, BDCA1+ mDCs, total monocytes, CD14+ monocytes, NK cells and CD56low NK cells exhibited the opposite trend (p < 0.05). The levels of total pDCs and BDCA1+ mDCs in the peripheral blood were significantly lower in the cervical cancer patients than in the precancerous lesion patients, while the proportion of CD16+ monocytes was elevated (p < 0.05). In addition, some lymphocyte subsets, especially CD4+ cells and CD8+ cells, and the CD4+/CD8+ cell ratio were closely associated with clinicopathological and prognostic parameters.
CONCLUSIONS: These results suggested that distinct alterations in infiltrating lymphocyte subsets occurred in the tumor and were associated with clinicopathological and prognostic parameters. Systemic impairment of the immune system may occur in the antitumor response of cervical cancer patients.

Entities:  

Keywords:  Cervical cancer; Clinicopathological variables; Lymphocyte subsets; Prognosis; Tumor immunology

Year:  2020        PMID: 32131750     DOI: 10.1186/s12885-020-6633-x

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  12 in total

1.  Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Ryuichiro Sawada; Takashi Akiyoshi; Yusuke Kitagawa; Yukiharu Hiyoshi; Toshiki Mukai; Toshiya Nagasaki; Tomohiro Yamaguchi; Tsuyoshi Konishi; Noriko Yamamoto; Masashi Ueno; Yosuke Fukunaga
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

2.  Establishment and Clinical Application of a Method for Detecting T Lymphocyte Subsets by Cellular Immunochip Technology.

Authors:  Chen Chen; Yan-Mei Liu; Shu-Xia Xuan; Mei-Fang Zhou; Peng Zhou; Bin Cheng; Jin-Duan Lin; Wei-Guo Yin; Lin-Hai Li
Journal:  J Inflamm Res       Date:  2021-12-31

3.  Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients.

Authors:  Swati Garg; Usha Shekhawat; Rajaat Vohra; Reshu Gupta
Journal:  J Obstet Gynaecol India       Date:  2022-02-24

4.  Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.

Authors:  Hui Yao; Xiya Jiang; Hengtao Fu; Yinting Yang; Qinqin Jin; Weiyu Zhang; Wujun Cao; Wei Gao; Senlin Wang; Yuting Zhu; Jie Ying; Lu Tian; Guo Chen; Zhuting Tong; Jian Qi; Shuguang Zhou
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

5.  Influence of chemoradiation on the immune microenvironment of cervical cancer patients.

Authors:  J M Herter; M Kiljan; S Kunze; M Reinscheid; O Ibruli; J Cai; L Niu; I Heßelmann; M Trommer; G S Herter-Sprie; C Köhler; S Marnitz
Journal:  Strahlenther Onkol       Date:  2022-10-17       Impact factor: 4.033

6.  An Innovative Immune Score-Based Prognostic Nomogram for Patients with Cervical Cancer.

Authors:  Xingling Qi; Yipeng Fu; Meng Zhang; Chong Lu; Yumeng Wang; Jing Peng; Guiling Li
Journal:  Biomed Res Int       Date:  2020-11-07       Impact factor: 3.411

7.  CCR7 Has Potential to Be a Prognosis Marker for Cervical Squamous Cell Carcinoma and an Index for Tumor Microenvironment Change.

Authors:  Wei-Jie Tian; Peng-Hui Feng; Jun Wang; Ting Yan; Qing-Feng Qin; Dong-Lin Li; Wen-Tong Liang
Journal:  Front Mol Biosci       Date:  2021-04-01

8.  A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Authors:  Xiaoling Xu; Ding Wang; Wei Chen; Na Li; Rafal Suwinski; Antonio Rossi; Rafael Rosell; Jianxiang Zhong; Yun Fan
Journal:  Transl Lung Cancer Res       Date:  2021-12

9.  Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer.

Authors:  Shengnan Li; Gengpu Zhang; Yang Lu; Tiansuo Zhao; Chuntao Gao; Weishuai Liu; Yongjun Piao; Yanan Chen; Chongbiao Huang; Antao Chang; Jihui Hao
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244

10.  Intertwined leukocyte balances in tumours and peripheral blood as robust predictors of right and left colorectal cancer survival.

Authors:  Ramón Cantero-Cid; Karla Marina Montalbán-Hernández; Jenny Guevara; Alejandro Pascual-Iglesias; Elisa Pulido; José Carlos Casalvilla; Cristóbal Marcano; Cristina Barragán Serrano; Jaime Valentín; Gloria Cristina Bonel-Pérez; José Avendaño-Ortiz; Verónica Terrón; Roberto Lozano-Rodríguez; Alejandro Martín-Quirós; Elvira Marín; Eva Pena; Laura Guerra-Pastrián; Eduardo López-Collazo; Luis Augusto Aguirre
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.